Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00395460
Other study ID # 91536
Secondary ID Project DE 00562
Status Completed
Phase Phase 3
First received November 2, 2006
Last updated May 13, 2015
Start date September 2006
Est. completion date April 2007

Study information

Verified date May 2015
Source Bayer
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.


Description:

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.


Recruitment information / eligibility

Status Completed
Enrollment 147
Est. completion date April 2007
Est. primary completion date April 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Chinese origin, with known or suspected brain or spine diseases

Exclusion Criteria:

- Pregnancy

- Lactation

- Conditions interfering with MRI

- Allergy to any contrast agent or any drugs

- Participation in other trial

- Require emergency treatment

- Severely impaired liver and kidney functions

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic


Intervention

Drug:
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
Magnevist
0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)

Locations

Country Name City State
China Chinese PLA General Hosp. Beijing
China Jiangsu Province Hospital Nanjing Jiangsu
China Fudan University Huashan Hospital Shanghai
China The 1st Affiliated Hosp of the 4th Military Med Uni Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

China, 

References & Publications (1)

Liang Z; Ma L; Wang D; Huan Y; Li P; Yu J; Yao Z; Chen S; He H; Feng X and Breuer J. Efficacy and Safety of Gadobutrol (1.0 M) versus Gadopentetate Dimeglumine (0.5 M) for Enhanced MRI of CNS Lesions: A Phase III, Multicenter, SingleBlind, Randomized Stud

Outcome

Type Measure Description Time frame Safety issue
Other Change in Contrast to Noise Ratio (CNR) Between Pre- and Post-contrast MRI Scan of CNS Lesions in Participants With Malignant Brain Tumor(s) / Brain Metastases CNR = (SI lesion - SI normal tissue) / SD background. SI lesion is the signal intensity in the lesion, SI normal tissue is the signal intensity in the normal tissue, and SD background is the standard deviation of the background noise. The signal intensity (SI) on the pre-contrast and on the post-contrast MR scans was to be measured in the enhanced lesion, normal tissue and background. Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
Other Change in Contrast to Noise Ratio (CNR) Between Pre- and Post-contrast MRI Scan of Participants With CNS Lesions Other Than Primary Malignant Brain Tumor(s) / Brain Metastases CNR = (SI lesion - SI normal tissue) / SD background. SI lesion is the signal intensity in the lesion, SI normal tissue is the signal intensity in the normal tissue, and SD background is the standard deviation of the background noise. The signal intensity (SI) on the pre-contrast and on the post-contrast MR scans was to be measured in the enhanced lesion, normal tissue and background. Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
Other Change in Number of Detected Lesions From Pre- to Post-contrast MRI Scan of CNS Lesions in Participants With Malignant Brain Tumor(s) / Brain Metastases Investigators and blinded readers (reader 2, 3 and 4) were to record the number of lesions in the magnetic resonance scans before and after injection of contrast agent. Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
Other Change in Number of Detected Lesions From Pre- to Post-contrast MRI Scan of Participants With CNS Lesions Other Than Primary Malignant Brain Tumor(s) / Brain Metastases Investigators and blinded readers (reader 2, 3 and 4= were to record the number of lesions in the magnetic resonance scans before and after injection of contrast agent. Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
Primary Change in Contrast to Noise Ratio (CNR) Between Pre- and Post-contrast Magnetic Resonance Imaging (MRI) Scan of Central Nervous System (CNS) Lesions CNR = (signal intensity [SI] lesion - SI normal tissue) / standard deviation (SD) background. SI lesion is the signal intensity in the lesion, SI normal tissue is the signal intensity in the normal tissue, and SD background is the standard deviation of the background noise. The signal intensity (SI) on the pre-contrast and on the post-contrast MR scans was to be measured in the enhanced lesion, normal tissue and background. Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
Secondary Change in Number of Detected Lesions From Pre- to Post-contrast MRI Scan The number of lesions in the magnetic resonance scans was recorded before and after injection of contrast agent for the investigators and all 3 blinded readers (reader 2, reader 3 and reader 4). Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
Secondary Change in Diagnostic Confidence From Pre- to Post-contrast Magnetic Resonance Imaging by Treatment The change in diagnostic confidence was assessed based on post-contrast compared to pre-contrast scans as "improved", "unchanged" or "worsened" for the investigators and all 3 blinded readers (reader 2, reader 3 and reader 4). Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
Secondary Change in Lesion Contrast Enhancement From Pre- to Post-contrast MRI The degree of contrast enhancement was recorded on a 4-point scale as follows: 1 = No: lesion is not enhanced. 2 = Moderate: lesion is weakly enhanced. 3 = Good: lesion is clearly enhanced. 4 = Excellent: lesion is clearly and brightly enhanced. In case of more than one lesion, the lesion with maximum enhancement was to be assessed. The change in lesion contrast enhancement was assessed based on post-contrast in comparison to pre-contrast scans for the investigators and all 3 blinded readers (reader 2, reader 3 and reader 4). Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
Secondary Change in Lesion Delineation Between Pre- and Post-contrast MRI Scan of CNS Lesions Lesion delineation was recorded on a 4-point scale as follows: 1 = None: no or unclear delineation of the boundary between lesion and surrounding tissue; 2 = Moderate: some aspects of border delineation covered; 3 = Good: almost clear delineation, but not complete on relevant slices; 4 = Excellent: sharp and complete delineation. In case of more than one lesion, the lesion with maximum enhancement was assessed. Change in lesion delineation was assessed based on post-contrast in comparison to pre-contrast scans for investigators and all 3 blinded readers (reader 2, reader 3 and reader 4). Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast) No
See also
  Status Clinical Trial Phase
Recruiting NCT05778279 - Role of New High Resolution Ultrasonographic Modalities for Diagnosis of Fetal Nervous System Anomalies
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Recruiting NCT05590884 - Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age Phase 2
Recruiting NCT06010823 - Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants N/A
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01211873 - Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Recruiting NCT05968976 - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET N/A
Not yet recruiting NCT05892510 - Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke Phase 2/Phase 3
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A
Completed NCT04283253 - Predictors of Response in Chronic Stroke N/A
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Completed NCT02368223 - Feasibility of the Portable YouGrabber System N/A
Completed NCT05815836 - Precision Medicine in Stroke
Completed NCT01445639 - Dexmedetomidine in Patients After Intracranial Surgery Phase 4
Completed NCT00995215 - Sub-study to Spinal Cord Stimulation to Restore Cough N/A
Completed NCT00766363 - Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease Phase 1